阿片类药物影响胎儿大脑:重新审视脱毒治疗的争议
本文综述动物与人类脑组织及活体影像研究,指出阿片类药物对发育中少突胶质细胞、髓鞘化及多个脑区产生不良影响。结合医学监督下戒断的新数据,作者提出在首选药物辅助治疗的同时,为特定女性保留医学监督下阿片戒断选项的新照护范式。
要点
- 阿片类药物对胎儿大脑的不良影响应纳入脱毒治疗争议的考量。
- 动物与人类活体研究显示阿片类影响少突胶质细胞、髓鞘化及脑连接。
- 作者建议首选药物辅助治疗,并为特定女性保留医学监督下戒断选项。
核心结论
- 鉴于医学监督下戒断的新数据及阿片类药物对发育中胎儿大脑不良影响的 emerging 证据,需要一种新照护范式,包括首选的药物辅助治疗以及为特定女性提供医学监督下阿片戒断的选项。
- 两种治疗选项均应在整个孕期提供心理社会支持。
- 需要对阿片暴露对发育中人类大脑的影响及医学监督下戒断的影响进行更多研究,以确定合适候选者、最佳剂量递减方案及开始医学监督下戒断的孕周时机。
研究设计与样本
- 本文为综述,整合了动物研究、人类脑组织研究以及婴儿、儿童和成人活体脑研究的数据。
主要发现
- 动物和人类脑组织研究显示阿片受体存在于神经元、星形胶质细胞和少突胶质细胞。
- 动物、人类神经组织、成人脑及儿童和新生儿脑研究一致表明,阿片类药物对大脑产生不良影响,主要影响发育中的少突胶质细胞和髓鞘化(白质微结构)过程、脑区之间的连接以及多个脑区的大小,包括基底节、丘脑和小脑白质。
- 跨人类寿命的活体研究提示特定额-颞-边缘和额-皮层下(基底节和小脑)通路存在脆弱性,这些通路在人类胎儿大脑中也可能脆弱。
- 胎儿大脑中这些可重复变化的长期影响尚不清楚,但已提示可能造成持久损伤。
临床怎么用
- 作者建议,新照护范式应首选药物辅助治疗,同时为特定女性提供医学监督下阿片戒断的选项。
- 作者建议,两种治疗选项均应在整个孕期提供心理社会支持。
局限性
- 胎儿大脑中这些可重复变化的长期影响尚不清楚,但已提示可能造成持久损伤。
- 需要对阿片暴露对发育中人类大脑的影响及医学监督下戒断的影响进行更多研究,以确定合适候选者、最佳剂量递减方案及开始医学监督下戒断的孕周时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Medication-assisted treatment is recommended for individuals with an opioid use disorder, including pregnant women. Medication-assisted treatment during pregnancy provides benefits to the mother and fetus, including better pregnancy outcomes, reduced illicit drug use, and improved prenatal care. An alternative approach, medically supervised withdrawal (detoxification), has, in recent reports, demonstrated a low risk of fetal death and low rates of relapse and neonatal abstinence syndrome. The rates of relapse and neonatal abstinence syndrome are questioned by many who view medically supervised withdrawal as unacceptable based on the concern for the potential adverse consequences of relapse to mother and baby. The impact of opioids on the fetal brain have not been integrated into this debate. Studies in animals and human brain tissues demonstrate opioid receptors in neurons, astroglia, and oligodendrocytes. Age-specific normative data from infants, children, and adults have facilitated investigation of the impact of opioids on the human brain in vivo. Collectively, these studies in animals, human neural tissue, adult brains, and the brains of children and newborns demonstrate that opioids adversely affect the human brain, primarily the developing oligodendrocyte and the processes of myelinization (white matter microstructure), connectivity between parts of the brain, and the size of multiple brain regions, including the basal ganglia, thalamus, and cerebellar white matter. These in vivo studies across the human lifespan suggest vulnerability of specific fronto-temporal-limbic and frontal-subcortical (basal ganglia and cerebellum) pathways that are also likely vulnerable in the human fetal brain. The long-term impact of these reproducible changes in the fetal brain in vivo is unclear, but the possibility of lasting injury has been suggested. In light of the recent data on medically supervised withdrawal and the emerging evidence suggesting adverse effects of opioids on the developing fetal brain, a new paradigm of care is needed that includes the preferred option of medication-assisted treatment but also the option of medically supervised opioid withdrawal for a select group of women. Both these treatment options should offer mental health and social services support throughout pregnancy. More research on both opioid exposure on the developing human brain and the impact of medically supervised withdrawal is required to identify appropriate candidates, optimal dose reduction regimens, and gestational age timing for initiating medically supervised withdrawal.
引用
- Caritis SN, Panigrahy A. Opioids affect the fetal brain: reframing the detoxification debate. Am J Obstet Gynecol. 2019. PMID: 31323217. doi:10.1016/j.ajog.2019.07.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。